HOMA-IR

← Back to Lab Reference Library

Category: Metabolic Health  |  Also known as: Homeostatic Model Assessment of Insulin Resistance, Insulin Resistance Index  |  Sample: Serum; requires both fasting insulin AND fasting glucose (8 to 12 hr fast)

1. What This Test Measures

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a calculated index, not a direct lab measurement, derived from two fasting blood values: insulin and glucose. The formula is:

The model was developed by Matthews and colleagues in 1985 at Oxford University and is based on the physiological relationship between insulin and glucose in the fasting state. In a person with normal insulin sensitivity, the pancreas produces a modest amount of insulin sufficient to maintain normal fasting glucose. As insulin resistance develops, the pancreas compensates by producing progressively more insulin. HOMA-IR captures this compensatory response by integrating both values into a single score.

A higher HOMA-IR score means more insulin is required to maintain the same glucose level, indicating greater insulin resistance. HOMA-IR is one of the most widely validated clinical tools in metabolic medicine and has been used in thousands of peer-reviewed studies as the reference standard for insulin resistance assessment in research settings.

2. Why This Test Matters

Insulin resistance is the central metabolic dysfunction underlying type 2 diabetes, cardiovascular disease, metabolic syndrome, PCOS, non-alcoholic fatty liver disease, and a growing list of cancers and neurological conditions. HOMA-IR provides a precise, quantified measure of that dysfunction with critical advantages over conventional diabetes screening:

• Detects resistance before glucose rises: Blood glucose and HbA1c only become abnormal after beta-cell function has already declined. HOMA-IR captures insulin resistance while the pancreas is still compensating, often 10 to 20 years before a diabetes diagnosis.
• More sensitive than fasting glucose alone: A fasting glucose of 95 mg/dL with a fasting insulin of 18 µIU/mL yields a HOMA-IR of 4.2, clear insulin resistance, yet both individual values fall within "normal" ranges on a standard lab report.
• Quantifies severity: Unlike a simple fasting glucose, HOMA-IR provides a continuous score that allows tracking of improvement or worsening over time in response to interventions.
• Cardiovascular risk: Elevated HOMA-IR is independently associated with hypertension, dyslipidemia, endothelial dysfunction, and increased cardiovascular event risk beyond its association with diabetes.
• PCOS and hormonal health: Insulin resistance drives androgen excess in PCOS. HOMA-IR is a critical component of PCOS evaluation and treatment monitoring.
• Non-alcoholic fatty liver disease (NAFLD): HOMA-IR is directly correlated with hepatic fat accumulation and NAFLD severity.
• Cancer biology: Chronic hyperinsulinemia, reflected by elevated HOMA-IR, is a recognized driver of increased cancer risk across multiple tumor types via IGF-1 pathway activation.

3. How to Calculate Your HOMA-IR

You need two fasting lab values, both drawn from the same blood draw after an 8 to 12 hour fast:

Step	Action	Example
1	Find your fasting insulin (µIU/mL)	10 µIU/mL
2	Find your fasting glucose (mg/dL)	95 mg/dL
3	Multiply insulin x glucose	10 x 95 = 950
4	Divide by 405	950 / 405 = 2.35 (Insulin Resistant)

If your glucose is reported in mmol/L instead of mg/dL, use the formula: HOMA-IR = (fasting insulin x fasting glucose) divided by 22.5.

4. Standard Lab Reference Range

HOMA-IR Score	Conventional Interpretation
Below 2.0	Normal insulin sensitivity (conventional)
2.0 to 2.9	Early insulin resistance
Above 3.0	Significant insulin resistance; diabetes risk elevated

The conventional cutoff of 2.0 misses a large window of early insulin resistance. Research consistently shows metabolic risk begins rising well below this threshold, which is why functional medicine practitioners use a tighter optimal target.

5. Optimal Functional Medicine Range

HOMA-IR Score	Functional Interpretation
Below 1.0	Optimal: excellent insulin sensitivity
1.0 to 1.9	Borderline: early metabolic stress; lifestyle optimization indicated
2.0 to 2.9	Mild to moderate insulin resistance; comprehensive intervention needed
3.0 to 5.0	Significant insulin resistance; cardiovascular and diabetes risk elevated
Above 5.0	Severe insulin resistance; comprehensive clinical evaluation required

6. Symptoms Associated With Elevated HOMA-IR

7. What Causes Elevated HOMA-IR

• High-glycemic diet: refined carbohydrates, added sugars, and ultra-processed foods chronically elevate insulin demand and drive insulin resistance
• Sedentary lifestyle and low muscle mass: skeletal muscle is the primary site of insulin-mediated glucose disposal; reduced muscle mass dramatically impairs insulin sensitivity
• Visceral adiposity: abdominal fat secretes pro-inflammatory adipokines that directly impair insulin receptor signaling
• Poor sleep and sleep apnea: even one night of poor sleep measurably raises HOMA-IR; obstructive sleep apnea produces chronic intermittent hypoxia that severely impairs insulin sensitivity
• Chronic psychological stress: sustained cortisol elevation promotes gluconeogenesis and directly antagonizes insulin action
• Gut dysbiosis and intestinal permeability: bacterial endotoxins (LPS) entering circulation trigger inflammatory pathways that impair insulin receptor signaling
• Thyroid dysfunction: hypothyroidism reduces metabolic rate and impairs glucose clearance
• Frequent eating and snacking: eliminates metabolic rest periods required for insulin receptor recovery
• Medications: corticosteroids, atypical antipsychotics, thiazide diuretics, beta-blockers
• Environmental toxins: persistent organic pollutants, BPA, and phthalates are endocrine disruptors that impair insulin signaling

8. How to Improve This Marker

9. Related Lab Tests

HOMA-IR is most informative when interpreted alongside these related markers:

10. When Testing Is Recommended

• Anyone with abdominal weight gain, fatigue after meals, or difficulty losing weight
• Family history of type 2 diabetes, cardiovascular disease, or metabolic syndrome
• Elevated fasting glucose or triglycerides on standard labs
• PCOS or irregular menstrual cycles
• Non-alcoholic fatty liver disease (NAFLD)
• Hypertension, especially in younger patients
• Any individual over 35 as part of preventive metabolic screening
• Monitoring response to dietary, lifestyle, or medication interventions for insulin resistance
• Patients on medications known to impair insulin sensitivity: corticosteroids, antipsychotics

11. Clinical Perspective

12. Frequently Asked Questions